Innovative Medicines

Lead asset and pipeline

We’re continually expanding our portfolio of advanced medicines

SERPLULIMAB—OUR LEAD ONCOLOGY ASSET

Lead asset

Our lead asset serplulimab recently received a positive approval from CHMP of the EMA. Serplulimab is currently being evaluated for the treatment of ES-SCLC in a confirmatory bridging study in a US population. Serplulimab has been designated an orphan drug by the FDA and EC. Download information about serplulimab to learn more about:

Serplulimab as anchor asset
Unique mode of recognition
ES-SCLC competitive landscape
Launch timeline
Target patient population
Market forecasts

CHMP, Committee for Medicinal Products for Human Use; EMA, European Medicines Agency; EC, European Commission.

Pipeline

We have preferred access to a diverse number of assets through our parent company and our partners. Our pipeline encompasses assets in oncology as well as in immunology and glaucoma.

Clinical Trials

Our clinical trials validate serplulimab as our lead asset for the treatment of ES-SCLC. ASTRUM-005 is a study with positive results that showed significant improvement compared to chemotherapy and had unprecedented mOS of 15.8 months. To achieve FDA approval, Fosun has initiated the ASTRIDE trial to confirm the results of ASTRUM-005 to patients with ES-SCLC in the United States.

Capabilities

Fosun Pharma USA has the ability to leverage the global operations footprint of our parent company to include R&D, manufacturing, and commercialization systems. Highlights of our capabilities include: